Accès ouvert
2026
erratum
OpenAlex
Marcos Vidal-Manrique, Laura Hooijmaijers, Julia A.J. Teders, Elif Saf et autres
[This corrects the article DOI: 10.3389/fimmu.2026.1792303.].
nl, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Marcos Vidal-Manrique, Laura Hooijmaijers, Julia A.J. Teders, Elif Saf et autres
Adoptive Natural Killer (NK) cell transfer is a promising therapy for the treatment of cancer. We developed a GMP-compliant protocol to generate NK cells from hematopoietic stem and progenitor cells (HSPC-NK). However, the immunosuppressive tumor microenvironment - especially prostaglandin E2 (PGE2) signaling …
nl, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Laura Hooijmaijers, Marcos Vidal-Manrique, Bart Spils, Diede van Ens et autres
The adoptive transfer of natural killer (NK) cells represents a promising cancer therapy due to their intrinsic ability to distinguish between malignant and healthy cells in an allogeneic context, enabling off-the-shelf manufacturing possibilities. On demand availability of cryopreserved advanced therapy medicinal products …
nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Marcos Vidal-Manrique, Thomas Nieuwenstein, Laura Hooijmaijers, Paul K.J.D. de Jonge et autres
Ovarian cancer (OC) is the most lethal gynecological malignancy. As high numbers of Natural Killer (NK) cells in ascites associate with improved survival, the adoptive transfer of allogeneic NK cells is an attractive therapeutic strategy. An approach to further improve NK cell …
nl, us, bh
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Jorge Cuenca‐Escalona, Johanna Bödder, Beatriz Subtil, Marta Sánchez‐Sánchez et autres
Tumor-derived prostaglandin E2 (PGE2) impairs antitumor immunity by priming suppressive functions on various immune cell types, including dendritic cells (DCs). In this way, tumors mediate DC dysfunction and hamper their antitumoral activity. PGE2 is known to modulate DC function via signaling through …
nl, us, de
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
P.M.M. van Hauten, Laura Hooijmaijers, Marcos Vidal-Manrique, Anniek B. van der Waart et autres
Background aims Natural killer (NK) cell transfer is a promising cellular immunotherapy for cancer. Previously, we developed a robust method to generate large NK cell numbers from CD34 + hematopoietic stem and progenitor cells (HSPCs), which exhibit strong anti-tumor activity. However, since …
nl, us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Maria Karvouni, Marcos Vidal-Manrique, Katharina H. Susek, Alamdar Hussain et autres
Background aims Adoptive cell therapy with chimeric antigen receptor (CAR)-expressing natural killer (NK) cells is an emerging approach that holds promise in multiple myeloma (MM). However, the generation of CAR-NK cells targeting CD38 is met with obstacles due to the expression of …
se, us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Rens Peeters, Jorge Cuenca‐Escalona, Esther A. Zaal, Anna T. Hoekstra et autres
The importance of fatty acid (FA) metabolism in cancer is well-established, yet the mechanisms underlying metabolic reprogramming remain elusive. Here, we identify tetraspanin CD37, a prognostic marker for aggressive B-cell lymphoma, as essential membrane-localized inhibitor of FA metabolism. Deletion of CD37 on …
nl, de
(code pays fourni par la source)
2022
conference-abstract
OpenAlex
Maria Karvouni, Marcos Vidal-Manrique, Katharina H. Susek, Arnika Kathleen Wagner et autres
Accès ouvert
2022
article
OpenAlex
Maria Karvouni, Marcos Vidal-Manrique, Andreas Lundqvist, Evren Alici
century and has since resulted in multiple breakthroughs in different fields of medicine, such as neurology, cardiology, and oncology. Lately, cell and gene therapy are merging to provide cell products with additional or enhanced properties. In this context, adoptive transfer of genetically …
se
(code pays fourni par la source)